{"doi":"10.5588/ijtldopen.24.0343","title":"Impact of heteroresistance on treatment outcomes of people with drug-resistant TB","abstract":"BACKGROUND: in the same sample) has been identified in some people with TB, but its impact on treatment outcomes is unknown. METHODS: We used targeted deep sequencing to identify mutations associated with DR-TB and heteroresistance in culture samples of 624 people with DR-TB. We evaluated the association between heteroresistance and time to unfavorable treatment outcome using Cox proportional hazards regression. RESULTS: The proportion of drug-resistant isolates with a known mutation conferring resistance was lower for streptomycin (45.2%) and second-line injectables (79.1%) than for fluoroquinolones (86.7%), isoniazid (93.2%) and rifampin (96.5%). Fifty-two (8.3%) had heteroresistance, and it was more common for fluoroquinolones (4.6%) than rifampin (2.2%), second-line injectables (1.4%), streptomycin (1.7%), or isoniazid (1.3%). There was no association between heteroresistance and time to unfavorable outcome among people with multidrug-resistant TB (adjusted hazard ratio [aHR] 1.74, 95% CI 0.39-7.72) or pre-extensively DR-TB (aHR 0.65, 95% CI 0.24-1.72). CONCLUSIONS: Heteroresistance was relatively common (8.3%) among people with DR-TB in the Philippines. However, we found insufficient evidence to demonstrate an impact on unfavorable treatment outcomes.","journal":"IJTLD OPEN","year":2024,"id":445680,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":7,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9048,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":231919,"name":"Midori Kato‐Maeda","orcid":"0000-0003-0539-2472","position":1,"is_corresponding":false},{"id":1262068,"name":"Brian Schwem","orcid":"0000-0002-5742-204X","position":2,"is_corresponding":false},{"id":1262069,"name":"Angelo dela Tonga","orcid":"0000-0002-3749-2921","position":3,"is_corresponding":false},{"id":924552,"name":"Donna Mae G. Gaviola","orcid":"0000-0003-2393-4343","position":4,"is_corresponding":false},{"id":1262517,"name":"E. Lopez","orcid":null,"position":5,"is_corresponding":false},{"id":995916,"name":"C.L. Valdez","orcid":null,"position":6,"is_corresponding":false},{"id":1262518,"name":"A.R. Lim","orcid":null,"position":7,"is_corresponding":false},{"id":1262519,"name":"N. Hunat","orcid":null,"position":8,"is_corresponding":false},{"id":1262520,"name":"A.G. Sedusta","orcid":null,"position":9,"is_corresponding":false},{"id":1262521,"name":"C.A. Sacopon","orcid":null,"position":10,"is_corresponding":false},{"id":1262522,"name":"Gerardo Atienza","orcid":null,"position":11,"is_corresponding":false},{"id":1262523,"name":"E. Bulag","orcid":null,"position":12,"is_corresponding":false},{"id":1262070,"name":"Dajeong Lim","orcid":"0000-0003-3966-9150","position":13,"is_corresponding":false},{"id":1262524,"name":"Joseph Edwin Lacerna Bascuña","orcid":null,"position":14,"is_corresponding":false},{"id":1262071,"name":"Kiran Shah","orcid":"0000-0003-3097-2444","position":15,"is_corresponding":false},{"id":1262525,"name":"R.P. Basillio","orcid":null,"position":16,"is_corresponding":false},{"id":387482,"name":"Christopher A. Berger","orcid":"0000-0002-0034-7544","position":17,"is_corresponding":false},{"id":532559,"name":"M. Lopez","orcid":null,"position":18,"is_corresponding":false},{"id":573901,"name":"Śaunak Sen","orcid":"0000-0003-4519-6361","position":19,"is_corresponding":false},{"id":861629,"name":"Christopher J. Allender","orcid":"0000-0002-6808-7611","position":20,"is_corresponding":false},{"id":481302,"name":"Megan Folkerts","orcid":"0000-0001-7430-1701","position":21,"is_corresponding":false},{"id":307187,"name":"Ulaş Karaöz","orcid":"0000-0002-8238-6757","position":22,"is_corresponding":false},{"id":87686,"name":"Eoin Brodie","orcid":"0000-0002-8453-8435","position":23,"is_corresponding":false},{"id":287965,"name":"Satoshi Mitarai","orcid":"0000-0002-2288-077X","position":24,"is_corresponding":false},{"id":924555,"name":"Anna Marie Celina Garfin","orcid":"0000-0003-3793-2429","position":25,"is_corresponding":false},{"id":1262072,"name":"Maria Cecilia G. Ama","orcid":"0000-0001-5652-889X","position":26,"is_corresponding":false},{"id":376250,"name":"David M. Engelthaler","orcid":"0000-0001-5945-059X","position":27,"is_corresponding":false},{"id":315466,"name":"Adithya Cattamanchi","orcid":"0000-0002-6553-2601","position":28,"is_corresponding":false},{"id":924554,"name":"Raul V. Destura","orcid":"0000-0002-2844-0142","position":29,"is_corresponding":false},{"id":557411,"name":"Rebecca Crowder","orcid":"0000-0001-6374-3088","position":0,"is_corresponding":true}],"reference_count":25,"raw_metadata":null,"created_at":"2026-07-19T02:01:46.243344Z","pmid":"39398438","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}